15038 studies
This rapid review aimed to evaluate the effects of GLP-1 RAs on eating behaviors and eating disorder risk. Databases were searched to January 2025 to identify studies evaluating GLP-1 RA treatment for adolescents or adults with obesity or Type 2 diab…
BACKGROUND: Cardiac microvascular injury from hyperlipidaemia and hyperglycaemia is associated with increased major adverse cardiovascular events (MACE). Semaglutide, a long-acting GLP-1 receptor agonist, reduces diabetic cardiovascular complications…
Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that has found widespread popularity as a weight loss product. Initially developed as a treatment for diabetes, the drug acts to stimulate the secretion of insulin, as well as suppress appetite…
AIM: To pool the incremental net benefits (INBs) of using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treating obesity without diabetes. MATERIALS AND METHODS: PubMed, Embase, EconLit, CEA Registry, ProQuest Dissertation and Theses Globa…
OBJECTIVE: This study aimed to assess weight and safety outcomes in a large national cohort of patients with overweight and obesity treated with GLP-1 medications via telehealth. METHODS: Data were obtained from deidentified EHRs for a random sample…
OBJECTIVE: To understand delivery features and intervention strategies of adolescent weight management interventions which may influence eating disorder risk. METHODS: Systematic searches in four databases and two trial registries to identify randomi…
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is an increasingly prevalent condition that poses significant public health challenges. Affecting nearly 30% of the global p…
BACKGROUND AND OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor…
OBJECTIVE: To examine the effects of oral semaglutide on kidney outcomes in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: SOUL (NCT03914326), a d…
Obesity-induced reproductive dysfunction is driven by chronic low-grade inflammation and metabolic dysregulation. The potential modulatory effect of GLP-1RAs on the interplay mechanisms of inflammation and metabolic dysregulation in obesity-induced r…
BACKGROUND: Antio-besity medications (OMs) are increasingly used in youth before and after metabolic and bariatric surgery (MBS), but their impact on surgical outcomes remains unclear. OBJECTIVES: This study examined whether perioperative OM exposure…
This study aims to compare the single-dose pharmacokinetic profiles of semaglutide administered via sublingual, oral, and injectable routes in Sprague-Dawley rats. Semaglutide was delivered sublingually in a proprietary anhydrous suspension vehicle.…
Obesity, a global public health crisis driven by complex interactions of genetic, environmental, and behavioral factors, necessitates innovative therapeutic strategies. This review explores the pathogenesis of obesity, emphasizing genetic determinant…
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1-RAs) effectiveness in normalising prediabetes has been evaluated in recent randomised control trials (RCTs), but the data has not been synthesised to guide everyday clinical management. OBJ…
Lysosome-targeting chimeras (LYTAC) represent a revolutionary technology for targeted protein degradation. However, the scarcity of highly efficient lysosomal transport receptors poses a major bottleneck to LYTAC advancement. In previous studies, we…